MedPath

to Assess the Eradication Rate of 14-day Bismuth/Amoxicillin/PCAB Triple Therapy for the Treatment of Helicobacter Pylori Infection

Not Applicable
Conditions
HELICOBACTER PYLORI INFECTIONS
Interventions
Drug: Bismuth amoxilillin potassium
Registration Number
NCT07142798
Lead Sponsor
Kaohsiung Medical University
Brief Summary

To assess the efficacy and safety of 14-day bismuth/amoxicillin/PCAB triple therapy for the treatment of Helicobacter pylori infection in Taiwan

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
200
Inclusion Criteria

Subjects infected with Helicobacter pylori.

Exclusion Criteria
  1. Those who are allergic to the drugs used in this research.
  2. Those who have had stomach surgery.
  3. Those with severe liver cirrhosis or uremia or malignant tumors.
  4. Women who are pregnant or breastfeeding. If you have drug allergies or pregnant women or breast-feeding women during the test period, you can withdraw from the test early.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Helicbpacyer pylori infectionBismuth amoxilillin potassiumHelicbpacyer pylori infection
Primary Outcome Measures
NameTimeMethod
Eradicaton rate of Helicobacter pylori6 weeks after finishing study drugs

13CUBT

Secondary Outcome Measures
NameTimeMethod
evaluate side effect2days after taking medicine

evaluate drugy side effect by Questionnaire

Trial Locations

Locations (1)

Kaohsiung Medical University Hospital

🇨🇳

Kaohsiung City, Taiwan

Kaohsiung Medical University Hospital
🇨🇳Kaohsiung City, Taiwan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.